October 6, 2017
Track this case
George H. Wu
Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.Additional or older documents may be available in Pacer.
Amgen Inc. has been “completely ignoring” its information-disclosure obligations under the federal biosimilars law in order to shield its biosimilar of blockbuster cancer drug Avastin, Genentech Inc. claims in a newly unsealed complaint.
Already a subscriber? Click here to login
Email (Professional email required)
PLEASE NOTE: A verification email will be sent to your address before you can access your trial.
Password (at least 6 characters required)